Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
A Study of BL-B01D1 + Axitinib Without or With Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
- Conditions
- Renal Cancer
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06962787
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
- Conditions
- Radiation TherapyTargeted TherapyImmunotherapyRenal Cancer Metastatic
- Interventions
- Radiation: Stereotactic Ablative Body Radiotherapy (SABR)
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06889649
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
- Conditions
- Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 75
- Registration Number
- NCT06860386
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Systemic Therapy Alone or with Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
- Conditions
- Renal Cell Carcinoma (Kidney Cancer)Kidney Cancer MetastaticRenal Cell Carcinoma Metastatic
- Interventions
- Radiation: Stereotactic body radiotherapy (SBRT)
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 252
- Registration Number
- NCT06726421
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Combination of Toripalimab and JS004 Therapy for ccRCC
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT06690697
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 825
- Registration Number
- NCT06495918
- Locations
- 🇺🇸
Associated Retina Consultant, Gilbert, Arizona, United States
🇺🇸Associated Retina Consultants, Ltd., Phoenix, Arizona, United States
🇺🇸Retinal Research Institute, LLC, Phoenix, Arizona, United States
CARE1 Pragmatic Clinical Trial
- Conditions
- Metastatic Kidney CancerMetastatic Kidney Carcinoma
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1250
- Registration Number
- NCT06364631
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇨🇿Masarykův onkologický ústav, Masaryk Memorial Cancer Institute (MOU), Brno, Czechia
🇨🇿Fakultní nemocnice Hradec Králová, University Hospital Hradec Kralove (FNHK), Hradec Kralove, Czechia
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
- Conditions
- Clear-cell Metastatic Renal Cell CarcinomaImmune Checkpoint InhibitorsCytoreductive Nephrectomy
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06279403
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
- Conditions
- Collecting Duct Carcinoma
- Interventions
- Drug: PD-(L)1 inhibitor
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06211114
- Locations
- 🇨🇳
Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06161558
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.